VivoSeq
Other

Intermittent Claudication

0

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Intermittent Claudication is an early-stage landscape with 0 programs across 5 companies. The most active players are Kos Pharmaceuticals, Genovate Biotechnology Co., Ltd.,, UCB.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

81/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kos Pharmaceuticals

0 programs

PreclinicalG

Genovate Biotechnology Co., Ltd.,

0 programs

PreclinicalUCB logo

UCB

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalD

Diffusion Pharmaceuticals Inc

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

23

clinical trials

Completed13 · 57%
Unknown status4 · 17%
Terminated3 · 13%
Recruiting3 · 13%

Clinical Trials

Trial Activity

23 trials

The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication
Recruiting·—·Phase 1·NCT04800692·10 enrolled
Effect of Breather in COPD Patients with Intermittent Claudication
Recruiting·—·N/A·NCT06529185·60 enrolled
MetfOrmin BenefIts Lower Extremities With Intermittent Claudication
Recruiting·VVA Office of Research and Development·Phase 3·NCT05132439·200 enrolled
Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication
Completed·—·Phase 2·NCT00102050·390 enrolled
Patients With Intermittent Claudication Injected With ALDH Bright Cells
Completed·TThe University of Texas Health Science Center, Houston·Phase 2·NCT01774097·82 enrolled
Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication
Completed·UUniversity of Virginia·Phase 2·NCT01890135·31 enrolled
EW-A-401 to Treat Intermittent Claudication
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT00080392·10 enrolled
Prostaglandin E1 in Outpatients With Intermittent Claudication
Completed·UCB logoUCB·Phase 3·NCT01263925·561 enrolled
Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication
Completed·KKos Pharmaceuticals·Phase 3·NCT00062556·366 enrolled
Caffeine and Intermittent Claudication
Completed·UUniversity of Aarhus·Phase 3·NCT00388128·80 enrolled
Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication
Completed·Sanofi logoSanofi·Phase 2·NCT01157871·36 enrolled
Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication
Completed·KKowa Research Institute, Inc.·Phase 2·NCT00783081·387 enrolled
Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients
Completed·SScience Valley Research Institute·Phase 4·NCT04853719·88 enrolled
Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication
Completed·DDiffusion Pharmaceuticals Inc·Phase 1/2·NCT00725881·48 enrolled
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
Completed·KKos Pharmaceuticals·Phase 3·NCT00071266·870 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)